All In Biotech

Drug Trial Radar · NCT07457190

Pharmacokinetic Study of Buagafuran Capsules in Participants With Hepatic Impairment and Normal Hepatic Function

Pharmacokinetic and Safety Study of Buagafuran Capsules in Participants With Hepatic Impairment and Normal Hepatic Function

Last checked: Nov 19, 2026Latest source record: Mar 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

24

Planned (sponsor's estimate)

Start

Mar 2026

Primary completion

Aug 2026

Study completion Dec 2026

Sponsor

Sponsor type
Industry
First posted
Mar 9, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Other
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study adopts a non-randomized, open label, parallel, single-dose design to evaluate the safety and pharmacokinetic characteristics of Buagafuran capsules in participants with hepatic impairment.

Conditions

  • Generalized Anxiety Disorder

Interventions

  • BuagafuranDrug

    participants to receive Buagafuran capsules 30 mg on an empty stomach on the morning of Day1

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pharmacokinetics of Buagafuran(Cmax)Time frame: from Day1 to Day3
  2. Pharmacokinetics of Buagafuran(AUC0-t)Time frame: from Day1 to Day3
  3. Pharmacokinetics of Buagafuran(AUC0-inf)Time frame: from Day1 to Day3

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing Union Pharmaceutical Factory Ltd

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.